fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Designation Underscores Urgent Need for New Antifungals Targeting Multidrug-Resistant Pathogens SAN DIEGO – Sept. 9, 2019 – Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral...
Cambridge, UK and Indianapolis, US – 5 September 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces its unaudited interim results for the six-month period ended 30 June 2019. A conference call will take place today at...
Lund, Sweden, 18:00 pm CET, 30 August 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids. During August, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31 August 2019, the number of shares in BONESUPPORT HOLDING AB...
Lund, Sweden, 10.00 am CET, 21 August 2019 – BONESUPPORT™, listed on Nasdaq Stockholm – an emerging leader in orthobiologics for the management of bone voids, announces that the patient enrollment schedule for the ongoing FORTIFY study is extended. Providing strong clinical evidence in support of its core technology, CERAMENT, is one of the cornerstones...
Cambridge, UK and Indianapolis, US – 16 August 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 106,997 Ordinary Shares of...
Cambridge, UK and Indianapolis, US –  12 August 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, will issue its interim results for the six-month period ended 30 June 2019 on Thursday 5 September 2019. A conference call will...
Lund, Sweden, 18:00 CET 31 July 2019 –  During July, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31 July 2019, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 52,351,417 shares, of which 51,846,417 are ordinary shares with one...
Lund, Sweden, 08.00 am CET, 25 July 2019 – BONESUPPORT™, listed on Nasdaq Stockholm – BONESUPPORT HOLDING AB (publ) – listed on Nasdaq Stockholm – an emerging leader in orthobiologics for the management of bone voids, today publish the financial report for thean emerging leader in orthobiologics for the management of bone injuries, today publishes...
Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that it is raising its Outlook for 2019.  This improvement is primarily driven by better than expected uptake of de novo use of Envarsus XR® (tacrolimus extended-release tablets) following the launch of the new indication in January of this year.  In addition to the better than expected de...
1 2 3 4 60

Lundbeckfonden Ventures

Nyheder

Acacia Pharma Group PLC – PDMR Dealing/Issue of Equity
1. oktober 2019
Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)
30. september 2019
Acacia Pharma Group PLC – Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020
26. september 2019